Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

So far, Altmetric has seen 19 X posts from 16 X users, with an upper bound of 68,304 followers.

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. https://t.co/L62CduexLn

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. https://t.co/XQJPE0qrYV

#JITC Research: Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma https://t.co/XcbQ3Q1A9d https://t.co/rsjuuo8cwz

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 15 additional X posts.